Breast Cancer Clinical Trial
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
Summary
This phase II trial studies how well radiation therapy works in treating post-menopausal women with early stage breast cancer undergoing surgery. Radiation therapy uses high energy x rays to kill tumor cells. This may be an effective treatment for breast cancer.
Full Description
PRIMARY OBJECTIVE:
I. For select patients with early stage breast cancer undergoing wide local excision followed by single fraction radiation therapy (SFRT), we will evaluate rates of observer-rated toxicity, cosmetic outcomes and patient satisfaction, objective measures of toxicity and quality of life as well as delivery of intended dose.
SECONDARY OBJECTIVE:
I. Locoregional control reported at five years.
OUTLINE:
Patients undergo wide local excision breast surgery and SFRT over 60-100 minutes once negative margins are obtained.
After completion of study treatment, patients are followed at 1 week, 1 month, 3 months, and then every 6 months for 2 years.
Eligibility Criteria
Inclusion Criteria:
Core needle biopsy (e.g. Mammotome, core, stereotactic, ultrasound guided) showing invasive mammary cancer (with or without concomitant ductal carcinoma or lobular carcinoma in situ) or ductal carcinoma in situ; acceptable histologic types of invasive mammary cancer include ductal, tubular, mucinous, papillary, cribriform and "NOS" (not otherwise specified); invasive lobular cancer is excluded
Age >= 50 years and postmenopausal with no menses for at least one year prior to study enrollment
Age > 70 years with invasive breast cancer clinical size =< 3 cm OR Age 50 - 70 years with invasive breast cancer clinical size =< 1.5 cm OR Age >= 50 years and postmenopausal with any grade ductal carcinoma in situ (DCIS) clinical extent =< 1.5 cm (clinical tumor size will be determined by pre-operative breast imaging-mammography, ultrasound and/or magnetic resonance imaging; in cases of multiple measurements, the largest recorded single dimension will be used to determine eligibility)
Hormone receptor status
Estrogen or progesterone receptor positive or
Estrogen and progesterone receptor negative and clinical tumor size =< 1.0 cm
Human epidermal growth factor receptor 2 (HER2)/neu negative on the core biopsy analysis defined as 0 or 1+ by immunohistochemistry or not amplified by fluorescent in situ hybridization analysis
Tumor >= 0.5 cm from skin as defined by breast ultrasound
Unicentric tumor
Axillary lymph nodes negative by pre-operative physical examination in all cases and pathologic examination from surgery for invasive disease
Negative surgical margins, defined as no margin-labeling ink on tumor cells from margin evaluation
Exclusion Criteria:
Initial core biopsy showing invasive lobular cancer
Estrogen receptor and progesterone receptor negative tumor with clinical size > 1 cm
Any Her 2+ breast cancer (immunohistochemistry 3+; or amplified by fluorescence in situ hybridization [FISH])
Cancer in a patient with a known inherited susceptibility mutation in breast cancer (BRCA)1 or BRCA2
Multicentric breast cancer (two foci of known cancer in the breast separated by greater than 5 cm, or in separate quadrants
Clinically or pathologically positive axillary lymph nodes
Any prior breast cancer
Prior breast radiation therapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Buffalo New York, 14263, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.